In summary, this phase 1/2 trial demonstrates the safety and strong clinical efficacy of autologous CAR-T therapy targeting CD19 and CD20 in r/r NHL, underscoring the potential of dual-antigen targeting in cell-based immunotherapy. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.